Navigation Links
New Reproductive Support Dietary Supplement, Pregnitude™, Now Available For Women Having Difficulty Conceiving
Date:5/7/2012

WEST ORANGE, N.J., May 7, 2012 /PRNewswire/ -- A new non-prescription Reproductive Support Dietary Supplement, Pregnitude™, which contains myo-inositol (2 g), plus folic acid (200 mcg), is now available for women who are having difficulty conceiving, Everett Laboratories announced today. In clinical studies, Pregnitude has been shown to help support ovulation function and menstrual cycle regularity as well as support the quality of a woman's eggs.

"Everett Labs is proud to make this new, important contribution to women's health. With Pregnitude, we're thrilled to provide a new option to support women who are having difficulty conceiving. We are confident that obstetricians and gynecologists around the country will find this a valuable alternative for women to support the ovulation frequency, regularity and quality of eggs," said Lucas Sigman, Chief Executive Officer, Everett Laboratories, Inc.

Myo-inositol is a naturally occurring substance produced in the human body that belongs to the vitamin B complex group and is found naturally in many foods such as fruits, cereals with high bran content, nuts and beans. Both myo-inositol and folic acid are considered to be important nutrients for women who are trying to become pregnant.

Approximately 6.1 million women in the United States have difficulty getting pregnant, according to the Centers for Disease Control and Prevention (CDC). 

"There is a tremendous need for support of couples having difficulty conceiving. They're often left frustrated and anxious, and the stress can compound the problem. Pregnitude can help support ovulation function, menstrual cycle regularity, and quality of eggs during this difficult time," said Scott Eder, M.D., Medical Director, Everett Laboratories and a board-certified obstetrician and gynecologist who practices in Lawrenceville, NJ.

Pregnitude is a powder formulation that is mixed with water and taken twice a day, in the morning and evening. It is available without a prescription at most major retail pharmacies and can be found behind the pharmacy counter. Consumers can also order Pregnitude online, at www.pregnitude.com

Clinical Trials with Myo-inositol in Combination with Folic Acid

Controlled clinical studies have demonstrated that supplementation with myo-inositol has a beneficial effect on ovulatory function, improving ovulation frequency, promoting menstrual cycle regularity and improving the quality of oocytes, or immature eggs.

"The results of the clinical trials with myo-inositol supplementation are particularly encouraging in supporting ovarian function. We are thrilled to provide another tool to support women wishing to become pregnant," said Dr. Eder.

Side effects and Who Should Not Use Pregnitude

Pregnitude is generally well tolerated. Women may experience gastrointestinal effects such as nausea and diarrhea when taken at high doses. Pregnitude should not be taken by anyone with a known hypersensitivity to either myo-inositol or folic acid. Folic acid should not be taken by anyone with untreated or uncomplicated pernicious anemia and those with anaphylactic sensitivity to folic acid. In addition, high doses of myo-inositol may have additive effects when taken concurrently with selective serotonin reuptake inhibitor (SSRI) and selective serotonin norepinephrine reuptake inhibitor (SNRI) antidepressant medications. Women who take these medications should talk to their doctor before using Pregnitude.

About Everett Laboratories, Inc.

Everett Laboratories Inc. is a New Jersey-based women's healthcare pharmaceutical company that has been providing essential pharmaceutical and nutritional products for four decades. Everett Laboratories Inc. is a subsidiary of The Chemo Group, a global healthcare corporation based in Spain with a presence in more than 30 countries. The company recently licensed products for stress urinary incontinence, fertility, and the Stuart Natal line of pre-natal vitamins. Everett Laboratories Inc. is dedicated to providing advanced treatments and innovative new products to address unmet needs for women and families and to improving women's health. The company strives to produce and market unique, first-in-class prescription and over the counter medications.


'/>"/>
SOURCE Everett Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
3. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
4. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
5. Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009
6. Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program
7. IVF FLORIDA Reproductive Associates Partners with The University of Miami School of Medicine and Jackson Memorial Health
8. Serono Symposia International Foundation in Collaboration With ESHRE Announces Public Competition in Reproductive Medicine
9. INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine
10. Reproductive Medicine Associates of NJ Receive Top National Award for Ground-Breaking IVF Research
11. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Halyard Health, Inc. (NYSE: HYH ) today ... 2017 outlook and related key planning assumptions. Executive Summary ... 2 percent increase compared to the prior year. ... million compared to net income of $15 million in the ... $24 million compared to adjusted net income of $27 million ...
(Date:2/27/2017)... , Feb. 27, 2017 Mederi Therapeutics ... 28 studies, representing 2468 patients who received  Stretta ... study entitled, " Systematic Review and Meta-Analysis of ... Radiofrequency for Treatment of Gastroesophageal Reflux Disease ", was ... Ronnie Fass , MD, head of the ...
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
Breaking Medicine Technology:
(Date:2/28/2017)... Los Angeles, CA (PRWEB) , ... February 28, 2017 , ... ... prostate cancer and vasectomies. In studying approximately 800 deaths from prostate cancer, the researchers ... prostate cancer and 20% more likely to get fatal prostate cancer. Although the increased ...
(Date:2/28/2017)... ... February 28, 2017 , ... TruClinic Inc. ... intelligence company based in New York. , “Ensuring an intuitive, user-friendly patient experience ... unaltered. Those two fundamental reasons are the reasons this acquisition is an obvious ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... 2017, from 4:30-5:30 p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville ... compliance, performance analytics, and engagement strategies. , The discussion will include best practices ...
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze Health ... announces Chris Brandl as its New Guest Director. , Brandl is a ... throughout his career. He began his professional career at Omnium Worldwide, now known ...
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
Breaking Medicine News(10 mins):